Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy

BACKGROUND: PD1 immune checkpoint blockade (αPD1 ICB) has shown unparalleled success in treating many types of cancer. However, response to treatment does not always lead to tumor rejection. While αPD1 ICB relies on cytotoxic CD8(+) T cells, antigen-presenting cells (APCs) at the tumor site are also...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Schetters, Sjoerd T T, Rodriguez, Ernesto, Kruijssen, Laura J W, Crommentuijn, Matheus H W, Boon, Louis, Van den Bossche, Jan, Den Haan, Joke M M, Van Kooyk, Yvette
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7371367/
https://ncbi.nlm.nih.gov/pubmed/32690667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000588
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados